In mice, composition of the gut microbiome modulates therapeutic activity and anti-PD-1 and anti-programmed death-ligand 1(PD-L1), and administration of FMT promotes anti-PD-1 efficacy in melanoma bearing mice (129–131). This evidence concerns the gene PDCD1 and melanoma.